9781848440777 1848440774 9781848444898 electronic book 1848444893 electronic book 1281941387 9781281941381
Alternate Call Number
G 99 COR.P
Summary
The issue of universal and free access to treatment is now a fundamental goal of the international community. Based on original data and field studies from Brazil, Thailand, India and Sub-Saharan Africa under the aegis of ANRS (the French nationalagency for research on Aids and viral hepatitis, this timely and significant book both assesses the progress made in achieving this objective and presents a rigorous diagnosis of the obstacles that remain. Placing particular emphasis on the constraints imposed by TRIPS as well as the poor state of most public health systems in Southern countries, the contributing authors provide a comprehensive analysis of the huge barriers that have yet to be overcome in order to attain free access to care and offer innovative suggestions of how they might be confronted. In doing this, the book renews our understanding of the political economy of HIV/AIDS in these vast regions, where the disease continues to spread with devastating social and economic consequences. This volume will be a valuable addition to the current literature on HIV/AIDS in developing countries and will find widespread appeal amongst students and academics studying economics, sociology and public health. It will also be of interest to international organizations and professional associations involved in the fight against pandemics.
Bibliography, etc. Note
Includes bibliographical references and index.
Formatted Contents Note
Foreword Introduction: A New Stage in the Fight against the HIV/AIDS Pandemic – An Economic Perspective Part I: Trips, Generic Drugs and Access to Care: The Post-2005 Issues 1. New Antiretroviral Treatments and Post-2005 TRIPS Constraints: First Moves towards IP Flexibilization in Developing Countries 2. New Trends in IP Protection and Health Issues in FTA Negotiations 3. Evolution of Prices and Quantities for ARV Drugs in African Countries: From Emerging to Strategic Markets Part II: Securing Free and Universal Access: Lessons From Brazil 4. The Brazilian Experience of ‘Scaling-up’: A Public Policy Approach 5. Technology Transfer Agreements and Access to HIV/AIDS Drugs: The Brazilian Case 6. Scaling Up and Reverse Engineering: Acquisition of Industrial Knowledge by Copying Drugs in Brazil 7. Compulsory Licensing in the Real World: The Case of ARV Drugs in Brazil Part III: Fighting Aids in the Heart of the Pandemic: Sub-Saharan and Low-Income Countries 8. HIV Prevalence Estimates: The New Deal in Sub-Saharan Africa since 2000 9. Cost-effectiveness of HIV Antiretroviral Therapies in Resource-limited Settings 10. ‘Fragility’: A Macro-dynamic Motive to Offer Quick and General Access to ART in LDC 11. Procurement Policies, Governance Models and ARV Availability in French-speaking African Countries: An Overview Part IV: Building the Future: Public Health Systems and the Free Access Challenge 12. The Public Health Approach to Antitretroviral Treatment: The Case of Cameroon 13. The Cost of Universal Free Access for Treating HIV/AIDS in Low-Income Countries: The Case of Senegal 14. Implementing Funding Modalities for Free Access: The Case for a ‘Purchasing Fund System’ to Cover Medical Care for PLWHA Index